ENSC Stock Overview
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States.
+ 2 more risks
Ensysce Biosciences, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$1.04|
|52 Week High||US$140.00|
|52 Week Low||US$1.00|
|1 Month Change||-56.30%|
|3 Month Change||-84.30%|
|1 Year Change||-98.26%|
|3 Year Change||-99.50%|
|5 Year Change||n/a|
|Change since IPO||-99.46%|
Recent News & Updates
|ENSC||US Biotechs||US Market|
Return vs Industry: ENSC underperformed the US Biotechs industry which returned -11.2% over the past year.
Return vs Market: ENSC underperformed the US Market which returned -20.6% over the past year.
|ENSC Average Weekly Movement||22.9%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.6%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: ENSC is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 23% a week.
Volatility Over Time: ENSC's weekly volatility (23%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis.
Ensysce Biosciences, Inc. Fundamentals Summary
|ENSC fundamental statistics|
Is ENSC overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ENSC income statement (TTM)|
|Cost of Revenue||US$15.58m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-10.31|
|Net Profit Margin||-1,115.64%|
How did ENSC perform over the long term?See historical performance and comparison